(Q51036113)

English

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study.

scientific article published on 25 September 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

relapsing-remitting multiple sclerosis

0 references

multiple sclerosis

0 references

author name string

Flavia Mattioli

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

C Stampatori

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

R Capra

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

publication date

25 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

Neurological Sciences

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

32

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

83-88

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

https://scigraph.springernature.com/pub.10.1007/s10072-010-0412-4

0 references

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Health-related quality of life in multiple sclerosis: effects of natalizumab

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Cognitive impairment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Paced auditory serial-addition task: a measure of recovery from concussion

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

A simple objective technique for measuring flexibility in thinking.

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b.

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Effect of interferon-beta-1b on cognitive functions in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Neuropsychologic status in multiple sclerosis after treatment with glatiramer

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS10072-010-0412-4

21 January 2018

Cognitive impairment in multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20872033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20872033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20872033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing–remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20872033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20872033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Italian standardization and classification of Neuropsychological tests. The Italian Group on the Neuropsychological Study of Aging]

1 reference

https://pubmed.ncbi.nlm.nih.gov/20872033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10072-010-0412-4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/20872033

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51036113&oldid=1407120058"